The Accu2i pMTA system, which is in worldwide distribution, is indicated for the coagulation of soft tissue during surgical procedures and recently received US Food and Drug Administration clearance.

The procedure involved a patient with hepatocellular carcinoma (HCC), or primary liver cancer, and was performed by Joseph Espat, professor and chief, surgical hepatobiliary oncology at Roger Williams Medical Center, Boston University.

The Acculis Accu2i pMTA system is a high power 2.45 GHz system that enables larger and faster ablations to be performed and this means that ablative therapy will now be available as an option for many more patients, the company said.

Microsulis Medical CEO Stuart McIntyre said they are delighted to report the first pMTA case in the US and consider it a milestone in providing a sophisticated, fast and effective method for ablating unwanted tissue masses.

"Current RFA and microwave systems have proven to have certain limitations when it comes to treating large and numerous cancerous tumors. With the Accu2i, surgeons can now perform larger and faster ablations that are suitable and less invasive for a broader group of patients," McIntyre said.